RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+4.29%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.63B
AUM Growth
+$6.63B
(+0.06%)
Cap. Flow
+$484M
Cap. Flow
% of AUM
7.3%
Top 10 Holdings %
Top 10 Hldgs %
41.1%
Holding
130
New
17
Increased
26
Reduced
9
Closed
10
Top Buys
| 1 |
Thermo Fisher Scientific
TMO
|
$238M |
| 2 |
Penumbra
PEN
|
$103M |
| 3 |
Tenaya Therapeutics
TNYA
|
$48.6M |
| 4 |
argenx
ARGX
|
$32.8M |
| 5 |
MacroGenics
MGNX
|
$29.9M |
Top Sells
| 1 |
QuidelOrtho
QDEL
|
$113M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$52.8M |
| 3 |
Protagonist Therapeutics
PTGX
|
$31.1M |
| 4 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$20.3M |
| 5 |
MiMedx Group
MDXG
|
$14.6M |
Sector Composition
| 1 | Healthcare | 91.48% |
| 2 | Financials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLU
51
DELISTED
BELLUS Health Inc.
BLU
| $30.4M | 0.46% |
4,968,017
| – | – |
|
52
Sight Sciences
SGHT
$199M
| $29.1M | 0.44% |
+1,283,871
| New | +$29.1M |
|
53
Johnson & Johnson
JNJ
$429B
| $27.5M | 0.42% |
170,542
| – | – |
|
54
Monte Rosa Therapeutics
GLUE
$309M
| $26M | 0.39% |
1,214,572
| – | – |
|
55
Clearside Biomedical
CLSD
$26.7M
| $25.2M | 0.38% |
4,206,765
| – | – |
|
56
Milestone Pharmaceuticals
MIST
$151M
| $24.6M | 0.37% |
4,315,102
| – | – |
|
57
PMV Pharmaceuticals
PMVP
$82.1M
| $24.1M | 0.36% |
809,863
+325,730
| +67% | +$9.71M |
|
|
GTH
58
DELISTED
Genetron Holdings Limited ADS
GTH
| $23.2M | 0.35% |
1,671,894
-146,268
| -8% | -$2.03M |
|
|
OYST
59
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $22.1M | 0.33% |
1,861,209
| – | – |
|
|
WHWK
60
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $21.3M | 0.32% |
+764,701
| New | +$21.3M |
|
61
ESSA Pharma
EPIX
$11.2M
| $21.1M | 0.32% |
2,637,192
-416,727
| -14% | -$3.33M |
|
62
Arbutus Biopharma
ABUS
$753M
| $20.3M | 0.31% |
4,733,323
-1,245,032
| -21% | -$5.34M |
|
63
InMode
INMD
$917M
| $19.9M | 0.3% |
124,999
| – | – |
|
|
CERE
64
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $19.7M | 0.3% |
666,666
+166,666
| +33% | +$4.92M |
|
|
RCOR
65
DELISTED
Renovacor, Inc.
RCOR
| $19.3M | 0.29% |
2,187,540
+1,350,000
| +161% | +$11.9M |
|
66
TELA Bio
TELA
$65.4M
| $19M | 0.29% |
1,391,619
-815
| -0.1% | -$11.1K |
|
67
Athira Pharma
ATHA
$15.5M
| $17.9M | 0.27% |
1,906,557
| – | – |
|
68
Adverum Biotechnologies
ADVM
$68.2M
| $16.2M | 0.24% |
7,483,757
+125,840
| +2% | +$273K |
|
69
NeoGenomics
NEO
$1.06B
| $14.9M | 0.22% |
311,111
| – | – |
|
70
UroGen Pharma
URGN
$896M
| $14.4M | 0.22% |
+857,464
| New | +$14.4M |
|
71
OraSure Technologies
OSUR
$230M
| $13.3M | 0.2% |
+1,174,722
| New | +$13.3M |
|
|
BWAY
72
Brainsway
BWAY
$296M
| $12.9M | 0.19% |
1,602,381
+200
| +0% | +$1.61K |
|
73
Immunic
IMUX
$79.4M
| $12.1M | 0.18% |
1,370,814
+450,000
| +49% | +$3.98M |
|
|
VINC
74
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $12.1M | 0.18% |
749,999
| – | – |
|
75
Exagen
XGN
$213M
| $11.2M | 0.17% |
821,414
| – | – |
|